{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:06:02Z","timestamp":1794027962640,"version":"4.8.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic bevacizumab is a novel targeted anti-angiogenic therapy for high-output cardiac failure (HOCF) in hereditary hemorrhagic telangiectasia (HHT) but published data is limited. This survey-based study measured physician-reported safety, effectiveness and current treatment practices for systemic bevacizumab in HHT-HOCF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A 27-item survey was sent to center directors of 31 international HHT Centers of Excellence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Response rate was 74% with centers reporting 150 total patients receiving systemic bevacizumab for HHT-HOCF. Approximately two-thirds of centers had treated \u22655 patients. All centers utilize a 5\u2009mg\/kg dose for induction treatment and most administer 6 doses (range, 4\u20136) every 2 weeks, although maintenance regimens varied considerably. Center directors reported bevacizumab to be effective, with 55% reporting significant improvement in cardiac index and HOCF symptoms in most patients treated with bevacizumab, although normalization of cardiac parameters was uncommon. Adverse events were uncommon with three-quarters of centers reporting adverse event rates &lt;\u200910%. Discontinuation for adverse events or ineffectiveness was rare. Bevacizumab was typically administered by hematologists and pulmonologists (50 and 39% of centers, respectively), with highly variable thresholds for initiation. Although half the centers reported difficulty with the insurance approval process, 70% of centers were ultimately able to obtain coverage for most or all of their patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Systemic bevacizumab is a widely-used therapy for HHT-HOCF with reasonable safety and effectiveness. HHT centers appear to vary considerably in maintenance treatment practices and disease severity thresholds for initiation of bevacizumab in HHT-related HOCF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-019-1239-6","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T09:03:10Z","timestamp":1573722190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1383","authenticated-orcid":false,"given":"Hanny","family":"Al-Samkari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan A.","family":"Albitar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E.","family":"Olitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne S.","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek N.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"issue":"9394","key":"1239_CR1","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/S0140-6736(03)14696-X","volume":"362","author":"Uichiro Fuchizaki","year":"2003","unstructured":"Fuchizaki U, Miyamori H, Kitagawa S, et al. Hereditary haemorrhagic telangiectasia (Rendu-Osler-weber disease). Lancet. 2003;362(9394):1490\u20134.","journal-title":"The Lancet"},{"issue":"21","key":"1239_CR2","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1002\/ajmg.a.32243","volume":"146A","author":"TG Letteboer","year":"2008","unstructured":"Letteboer TG, Mager HJ, Snijder RJ, et al. Genotype-phenotype relationship for localization and age distribution of telangiectases in hereditary hemorrhagic telangiectasia. Am J Med Genet A. 2008;146A(21):2733\u20139.","journal-title":"Am J Med Genet A"},{"issue":"7","key":"1239_CR3","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/jmg.40.7.494","volume":"40","author":"SA Abdalla","year":"2003","unstructured":"Abdalla SA, Geisthoff UW, Bonneau D, et al. Visceral manifestations in hereditary haemorrhagic telangiectasia type 2. J Med Genet. 2003;40(7):494\u2013502.","journal-title":"J Med Genet"},{"issue":"9","key":"1239_CR4","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3324\/haematol.2018.193003","volume":"103","author":"A Kritharis","year":"2018","unstructured":"Kritharis A, Al-Samkari H, Kuter DJ. Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective. Haematologica. 2018;103(9):1433\u201343.","journal-title":"Haematologica"},{"issue":"10","key":"1239_CR5","doi-asserted-by":"publisher","first-page":"e492","DOI":"10.3324\/haematol.2018.203968","volume":"103","author":"H Al-Samkari","year":"2018","unstructured":"Al-Samkari H, Kritharis A, Kuter DJ. Infections and vaccination in hereditary hemorrhagic telangiectasia: microbiological evidence-based considerations. Haematologica. 2018;103(10):e492\u20135.","journal-title":"Haematologica"},{"issue":"5","key":"1239_CR6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jhep.2007.12.022","volume":"48","author":"P Buonamico","year":"2008","unstructured":"Buonamico P, Suppressa P, Lenato GM, et al. Liver involvement in a large cohort of patients with hereditary hemorrhagic telangiectasia: Echo-color-Doppler vs multislice computed tomography study. J Hepatol. 2008;48(5):811\u201320.","journal-title":"J Hepatol"},{"issue":"9","key":"1239_CR7","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jama.2012.250","volume":"307","author":"S Dupuis-Girod","year":"2012","unstructured":"Dupuis-Girod S, Ginon I, Saurin JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA. 2012;307(9):948\u201355.","journal-title":"JAMA"},{"issue":"1","key":"1239_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jhep.2015.07.040","volume":"64","author":"EASL Clinical Practice Guidelines","year":"2016","unstructured":"Clinical Practice Guidelines EASL. Vascular diseases of the liver. J Hepatol. 2016;64(1):179\u2013202.","journal-title":"J Hepatol"},{"issue":"13","key":"1239_CR9","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJM200009283431305","volume":"343","author":"G Garcia-Tsao","year":"2000","unstructured":"Garcia-Tsao G, Korzenik JR, Young L, et al. Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med. 2000;343(13):931\u20136.","journal-title":"N Engl J Med"},{"issue":"2","key":"1239_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/jmg.2009.069013","volume":"48","author":"ME Faughnan","year":"2011","unstructured":"Faughnan ME, Palda VA, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet. 2011;48(2):73.","journal-title":"J Med Genet"},{"key":"1239_CR11","unstructured":"Garg N, Khunger M, Gupta A, et al. Optimal management of hereditary hemorrhagic telangiectasia. J Blood Med. 2014;5:191\u2013206."},{"issue":"1","key":"1239_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000072411","volume":"110","author":"A Cirulli","year":"2003","unstructured":"Cirulli A, Liso A, D\u2019Ovidio F, et al. Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol. 2003;110(1):29\u201332.","journal-title":"Acta Haematol"},{"issue":"6","key":"1239_CR13","first-page":"818","volume":"90","author":"H Sadick","year":"2005","unstructured":"Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica. 2005;90(6):818\u201328.","journal-title":"Haematologica"},{"issue":"2","key":"1239_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.mayocp.2017.11.013","volume":"93","author":"VN Iyer","year":"2018","unstructured":"Iyer VN, Apala DR, Pannu BS, et al. Intravenous Bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding. Mayo Clin Proc. 2018;93(2):155\u201366.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"1239_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/joim.12832","volume":"285","author":"H Al-Samkari","year":"2019","unstructured":"Al-Samkari H, Kritharis A, Rodriguez-Lopez JM, et al. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. J Intern Med. 2019;285(2):223\u201331.","journal-title":"J Intern Med"},{"issue":"11","key":"1239_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188943","volume":"12","author":"A Guilhem","year":"2017","unstructured":"Guilhem A, Fargeton AE, Simon AC, et al. Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): a retrospective study of 46 patients. PLoS One. 2017;12(11):e0188943.","journal-title":"PLoS One"},{"key":"1239_CR17","unstructured":"Cure HHT Foundation. Criteria for a North American Cure HHT Center of Excellence, 2017."},{"issue":"1","key":"1239_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13023-018-0982-4","volume":"14","author":"E Buscarini","year":"2019","unstructured":"Buscarini E, Botella LM, Geisthoff U, et al. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2019;14(1):28.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"1239_CR19","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/0194599818813521","volume":"160","author":"H Al-Samkari","year":"2019","unstructured":"Al-Samkari H. Systemic Bevacizumab for hereditary hemorrhagic telangiectasia: considerations from observational studies. Otolaryngol Head Neck Surg. 2019;160(2):368.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"1239_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5688\/aj720111","volume":"72","author":"JR Draugalis","year":"2008","unstructured":"Draugalis JR, Coons SJ, Plaza CM. Best practices for survey research reports: a synopsis for authors and reviewers. Am J Pharm Educ. 2008;72(1):11.","journal-title":"Am J Pharm Educ"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1239-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1239-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1239-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T19:28:44Z","timestamp":1605209324000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1239-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1239"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1239-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,14]]},"assertion":[{"value":"22 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was approved by the Institutional Review Board of the Mayo Clinic (approval number 14\u2013006516).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No individual person detail\/data contained within manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no disclosures relevant to the submitted work. Universal Disclosures: Al-Samkari: Consultancy (Agios, Dova, Moderna), Research Funding (Agios, Dova). Albitar: None. Olitsky: None. Clancy: None. Iyer: None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}